A new observational study offers one of the largest real-world examinations to date of how people are using BPC-157, where they are obtaining it and what outcomes are appearing in their clinical records.

The researchers analyzed de-identified electronic health records from a network covering approximately 15.2 million patients. Because BPC-157 is not an FDA-approved medication and does not have conventional prescription records, the research team used large language models to identify and organize relevant information contained in clinical notes. Physicians then reviewed samples of the extracted information to evaluate its accuracy.

The analysis identified 1,039 patients with documented BPC-157 use between 2020 and the second quarter of 2026. Newly confirmed users increased approximately 33-fold over that period, highlighting how quickly interest in the peptide has expanded.

Why Patients Reported Using BPC-157

A reason for using BPC-157 was documented for 644 patients. The most frequently reported reasons included:

• Pain, documented in 33% of all confirmed users

• Gastrointestinal concerns, including reflux, inflammatory bowel disease or gastritis, in 14%

• Previous injuries in 11%

• Post-surgical healing in 10%

• Performance-related goals in 4%

Among patients using BPC-157 for musculoskeletal concerns, commonly documented areas included the shoulder, knee, back, elbow and hip or pelvis.

The study does not establish that BPC-157 effectively treats any of these conditions. Instead, it describes why patients reported using it and the outcomes subsequently recorded in their clinical notes.

Most Patients Used Other Interventions at the Same Time

BPC-157 was frequently used as one part of a larger treatment strategy rather than as a standalone intervention. More than half of the confirmed users had documented use of at least one additional therapeutic agent.

The most commonly recorded co-therapies were testosterone, nonsteroidal anti-inflammatory drugs, TB-500 and corticosteroids. Some patients were also receiving physical therapy, undergoing surgery or participating in exercise and dietary counselling.

These overlapping interventions make it impossible to determine whether reported changes were caused by BPC-157, another treatment, the combination of therapies or non-treatment factors such as natural recovery and placebo effects.

Where Patients Obtained BPC-157

A source was documented for only 205 of the 1,039 confirmed users. Within that smaller group, 36% reportedly obtained BPC-157 from compounding pharmacies, while 35% obtained it from grey-market peptide vendors.

Other reported sources included wellness or weight-management clinics, retail outlets and online or telehealth vendors.

The route of administration was not available for most patients. When it was documented, oral use was most frequently recorded, followed by subcutaneous and intramuscular injection.

What the Clinical Notes Reported

A directional response was available for 354 patients, representing approximately one-third of the confirmed-user cohort. Among these assessable cases:

• 79% had documented symptomatic improvement

• 16% had no documented change

• 5% had documented worsening

Most improvements were reported by patients rather than independently observed by clinicians. Pain relief was the most frequently described improvement, followed by perceived wound or tissue healing and a return of physical function.

These percentages require careful interpretation. The other 685 confirmed users did not have a clearly documented response, meaning the 79% figure does not represent 79% of everyone who used BPC-157. It represents 79% of the smaller subgroup whose records contained an assessable direction of change.

The researchers also found no significant relationship between documented treatment duration and the likelihood of reported improvement.

Adverse Events May Be Underreported

Potential adverse events were infrequently documented. The most commonly recorded categories included neuropsychiatric symptoms, injection-site or dermatologic reactions and gastrointestinal complaints.

Among 129 patients with confirmed discontinuation, 46% reportedly stopped following advice from a clinician. Adverse effects were documented as the reason for stopping in 19%, while 16% discontinued because they believed the treatment was ineffective.

The authors cautioned that adverse events were likely underreported because the study relied on routine clinical documentation. Patients may not have discussed every symptom, and clinicians may not have recorded every detail associated with BPC-157 use.

What the Research Can and Cannot Tell Us

This study provides useful information about how BPC-157 is being used outside controlled clinical trials, but it does not establish safety or effectiveness.

The research was retrospective and depended on what patients and clinicians documented in medical notes. Dose and adherence information were generally unavailable, outcomes were not measured using standardized clinical protocols and many patients were using other treatments simultaneously.

Selection, reporting and confirmation bias may also have influenced the findings. People who experienced a noticeable outcome—positive or negative—may have been more likely to mention it than those who experienced no change.

The paper is also a preprint and had not undergone peer review when published.

Even with those limitations, the findings demonstrate that BPC-157 use is increasing faster than the formal human evidence supporting it. The study gives researchers a clearer picture of current use and identifies areas that require prospective investigation, including pharmacology, dosing, tolerability, product quality and controlled efficacy trials.

Original source: Rising Use of Unapproved BPC-157 and Associated Patient-Reported Outcomes Curated from Clinical Notes, posted September 7, 2026.

Editorial note: This study is a non-peer-reviewed preprint based on retrospective clinical-note analysis. BPC-157 is not currently approved by the FDA as a drug, and the reported outcomes should not be interpreted as proof of safety or effectiveness.